Obsidian Therapeutics
Biotechnology company developing controllable cell and gene therapies using its proprietary cytoDRiVE platform to provide precise, tunable control over therapeutic proteins expressed in engineered cells.
Website
https://www.obsidiantx.comLocation
Cambridge, Massachusetts, USA
Founded
2015
Investors
1
Categories
biotech, cell-therapy, gene-therapy, regulated-therapeutics
Notes
Obsidian Therapeutics is a biotechnology company developing controllable cell and gene therapies using its proprietary cytoDRiVE (Destabilizing Domain Regulation in Vivo for Expression) platform. This technology enables precise control over therapeutic proteins expressed in engineered cells by using oral small molecules.
The ability to regulate cell therapy activity addresses key safety and efficacy challenges in the field, potentially enabling therapies that can be dialed up or down based on patient needs.
Team
- Michael Bhirdo - Chief Executive Officer
- Andrew Bhirdo - Chief Operating Officer
Additional Research Findings
- Founded in 2015 in Cambridge, Massachusetts
- Backed by Novo Holdings
- Proprietary cytoDRiVE platform for controllable cell therapies
- Technology provides tunable control of therapeutic protein expression
- Focus on improving safety and efficacy of cell and gene therapies
- Strategic partnerships with major pharmaceutical companies
- Addresses critical need for controllable cell therapy approaches
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Novo Holdings | Hellerup, Denmark | biotech-focused | seedseries-a+3 | 13 |